Giulia C. Kennedy

Giulia C. Kennedy is Chief Scientific and Medical Officer for Veracyte. Since joining the diagnostics company in 2008 as part of the founding team, Dr. Kennedy has overseen the development of five commercialized genomic tests that resolve diagnostic uncertainty and are becoming standard of care. Through Dr. Kennedy’s scientific leadership, Veracyte continually pushes the boundaries of what is possible by using big data and machine learning to develop tests that answer critical clinical questions. Prior to Veracyte, Dr. Kennedy was Senior Director of Genomics Collaborations at Affymetrix, Inc. and led the transition of a novel microarray-based genotyping method from early research through product development and successful commercialization.

Previously, Dr. Kennedy was a scientific leader for the colon cancer and breast cancer gene discovery efforts at Chiron Corporation. Before that, she was a scientist at Millennium Pharmaceuticals, where she implemented genetic approaches to study diabetes. She holds a Ph.D. degree in Biochemistry and completed postdoctoral training at the University of California at San Francisco in the Biochemistry Department and Hormone Research Institute. Dr. Kennedy has published more than 60 articles in peer-reviewed scientific journals and is a co-inventor on more than 20 patents.